The pharmaceutical industry was no exception, which had a detrimental impact on the generic medication market. Later, due to the COVID-19 illness’s multiple opportunities to generate drugs to treat this infection, the market witnessed an increase in demand for generic pharmaceuticals. The dominance of this segment can largely be attributed to the availability of therapeutically effective weight management medications, regardless of whether their action is central or peripheral. The increasing prevalence of obesity, driven by factors such as high alcohol consumption, fast food intake, and sedentary lifestyles, also contributes to the growing demand for these products.
- In a modern clinical scenario, the administration of appropriate prescription drugs is critical for better clinical outcomes for almost every patient suffering from serious disorders.
- Enhanced manufacturing technologies and global access expansion contribute to the segment’s rapid market penetration.
- It is worth highlighting that the market for anti-obesity drugs in Asia-Pacific is expected to grow at a relatively higher CAGR (~40%), till 2035.
- This has led to increasing demand from patients due to their unmet clinical needs and demand for positive clinical outcomes.
Further, 2.5 billion adults aged 18 and above suffered from obesity, were as 890 million cases classified as obese. Thus, this highlights the growing need for effective solutions such as anti-obesity drugs, which help individuals to maintain their weight, improve their health, and tackle the global obesity problem. COVID-19 is testing is compulsory in the healthcare system, raising concerns about equity, exploding capacity, social safety nets, and data collection, The pharmaceutical supply chain is disturbed as drug shortages occur mainly in generic drugs. But now, several factors are straining the supply chain, increasing the potential for shortages and risks. The FDA approves patent and exclusivity protection for the branded drug developer to allow them to profit from their innovation and research for several years.
GlobalData
The rest of the world market comprises Latin America and the Middle East & Africa and is currently in a stage of growth. Increasing use of advanced prescription products and increasing healthcare expenditure are projected to fuel the market growth during the forecast period. Moreover, the others segment held a dominant share of the market in 2023, owing to the increasing launch and sales of drugs by key players and the rising number of prescriptions of these drugs by healthcare professionals across the globe. In terms of therapy, the market is segmented into oncology, central nervous system, vaccines, immunosuppressants, and others.
FIND TREATMENT:
In some cases, healthcare systems and hospitals may implement protocols to promote the use of generic drugs during shortages to optimize resource allocation and minimize disruptions in patient care. Moreover, the reliance on generic drugs during drug shortages addresses immediate supply challenges and contributes to the growth of the generic drug market in the long term. This creates an opportunity for healthcare providers, patients, and payers to recognize the value and reliability of generic medications, potentially leading to increased utilization and market growth for generic drugs beyond the period of shortage. Chronic diseases, such as diabetes, cardiovascular conditions, and respiratory disorders, are prevalent and require long-term medication use. As the population ages and the prevalence of chronic diseases increases, the need for cost-effective medication options becomes crucial. They contain the same active ingredients as their brand-name counterparts, ensuring similar therapeutic effects at a fraction of the cost.
However, the endocrinology, respiratory, and cardiovascular segments are anticipated to register lower CAGRs during the forecast period. The immunotherapy segment is expected to register a strong CAGR due to the presence of reliable products, such as Keytruda, and also increased research initiatives. • By drugtype, the simple generic segment is estimated to hold the highest market shareof 60.74% in 2024.
What Defines The Pharmaceutical Drugs Market?
- By distribution channel, the market is segmented into hospitals & clinics, retail pharmacies, and other distribution channels.
- The branded drugs segment dominated the market with the largest revenue share of 62.5% in 2024, attributed to patent exclusivity, strong marketing strategies, and clinical preference in specialty therapeutics.
- By drug type, the specialty drugs segment is expected to be the fastest-growing segment in the drugs market in the upcoming years.
- The affordability and accessibility of unbranded generics make them a preferred choice for healthcare providers, payers, and patients looking for cost savings and value-based healthcare solutions.
This can be attributed to a growing senior population, increased healthcare costs, an increase in chronic disease cases, and government attempts to encourage the use of generics. North America contributed 33.20% of 2024 global revenue, underpinned by mature substitution policies whereby generics fill more than 90% of prescriptions yet absorb only 18% of spend. The generic drugs market size in the region benefits from the FDA’s high approval cadence and from federal crackdowns on patent evergreening, moves that collectively accelerate early competition and erode branded monopolies. Nevertheless, inflation-linked input costs and upcoming price negotiation clauses will test profitability, pressuring companies to automate quality control, diversify suppliers, and optimize route-to-market economics. Several regions across the globe faced challenges in accessing medical care and treatment due to the escalation of country restrictions or lockdowns. These factors also limited the number of patient visits to hospitals, and the dispersion of prescriptions by healthcare professionals, further moderately limiting the demand and adoption of prescription drugs.
Furthermore, in 2023, drug spending in nonfederal hospitals decreased by 1.1%, totaling USD 37.1 billion, while expenditures in clinics increased by 15.0% to USD 135.7 billion. Clinic growth was driven by higher utilization, with a minor impact from new products and price changes. In nonfederal hospitals, lower utilization led to reduced spending, while new drugs and prices had a modest influence.
Generic Drugs Market Growth Factors
According to the CDC, with the rhinovirus accounting for at least 50% of cold cases, the impact is substantial, leading to approximately 22 million lost school days annually in the U.S., as reported by the CDC. The occurrence of cold is estimated at 1 billion cases each year among Americans, emphasizes the widespread demand for OTC drugs to alleviate symptoms and manage the effects of common colds. Many strategies such as mergers and acquisitions, product launch and development, collaborations, and partnership are being adopted widely to beat the competition. The competitive landscape is mainly driven by the rising demand for affordable medicines globally, the expiration of patents for blockbuster drugs, and less barriers for entry. Thesepharmacies serve as a crucial point of access for patients, giving them accessto generic medications for several conditions.
Associated Data
The emerging trend of self-medication, wider involvement in healthcare expenditures, and the ongoing process of converting some prescription drugs to OTC status also fosters market expansion. Moreover, the market is accelerating accessibility by the FDA, which has promoted pathways, like the ACNU, to allow the application of technology-enabled tools, such as self-selection questionnaires via mobile applications or pharmacy kiosks. The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter’s five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries.
Generic Drugs Market Size To Hit USD 77561 Billion By 2033
The orphan segment is anticipated to grow at a comparatively higher CAGR over the forecast period. The increasing clinical trials for the development of orphan drugs and rising approval by regulatory agencies are anticipated to increase the uptake of these drugs during the forecast period and drive the market growth. The U.S. OTC drugs market was valued at USD 49.9 billion in 2021 and witnessed lucrative growth to reach USD 50.3 billion in 2022 and USD 51.4 billion in 2023. During this period, the market growth was driven by the COVID-19 pandemic, which created increased demand for immunity boosters, vitamins, and other supplements. The rising focus on preventive care and the increasing trend to opt for self-medication have further boosted the growth.
A hub for drug dealing, particularly of this size, becomes a locus for drug use in the surrounding region. Shutting them down one by one will just create opportunities for the others to grow, or for new players to enter the market. Much as in High Point, the city would need to arrest all the dealers more or less simultaneously. The Parker administration, perhaps eager to signal a different tenor, has moved to end the $1 million in public funding that Prevention Point received under prior mayoralties.
The development of public awareness about obesity and its health impact through the social media platform, will encourage more individuals to seek the treatment, enabling market players to strengthen their position in this growing sector. Generic drugs are off-patent drugs that are bioequivalent to the original drug in terms of dosage, strength, quality, form, efficacy, intended use, side effects, and route of administration. In the United States, there has been a significant increase in the production of generic drugs, which are cheaper than the original drugs and do not require extensive research and testing. In addition, the introduction of generic drugs has improved patient access and saved taxpayers, employers, and insurers, sustaining the nation’s healthcare system.
Major Drug Market Trends Of The Past Decade
Government policies such as streamlined FDA approvals and substantial funding in biotechnology and innovative drug development encourage continuous the market expansion. Regulatory authorities, including the FDA, EMA, and regional agencies, enforce comprehensive guidelines to ensure the safety, efficacy, and quality of pharmaceutical products. The approval process involves extensive preclinical and clinical evaluations, impacting development timelines and costs. Pricing regulations, reimbursement policies, and patent laws significantly influence market access and adoption, with affordability and equitable access remaining key considerations in both developed and emerging markets. Alongside, nowadays these pharmacies are putting efforts into digital-first models, by facilitating online appointment booking, self-service kiosks, and digital medication information to meet developing consumer demands. The continuous transformation in the complete wellness hubs provides a range of services, which encompass health screenings, wellness products, and even mini-clinics under one roof.
Indeed, the most effective treatment approach for opioid use disorder is opioid agonist treatment (OAT) 50. Still, in the US, treatment coverage is estimated to be 28% and waiting times for treatment services can extend to several weeks 51. Furthermore, OAT in North America is usually not individualised, meaning that most patients receive either sublingual buprenorphine or oral methadone 52. Slow-release oral morphine and fast-acting agonists are utilised in Canada to some extent, but treatment barriers like waiting times and long-distance travel to reach clinics limit access to them 53, 54.
